Janus Henderson Group plc Discloses New 5.3% Stake in Tarsus Pharmaceuticals, Inc.

On May 15, 2026, Janus Henderson Group plc filed a Schedule 13G with the SEC, disclosing a new 5.3% ownership stake in Tarsus Pharmaceuticals, Inc. (TARS). As of the event date of March 31, 2026, the global investment firm beneficially owns 2,240,963 shares of common stock. Janus Henderson Group plc serves as the ultimate parent company for several SEC-registered investment advisers, including Janus Henderson Investors US LLC and Janus Henderson Investors UK Limited, which exercise investment and voting discretion over various managed portfolios. The filing indicates that the reporting person holds shared voting and dispositive power over the entire 2,240,963 shares. This acquisition represents a significant increase from a previous 0% position, crossing the 5% threshold for beneficial ownership disclosure. The securities were acquired in the ordinary course of business, and the filing confirms that the shares were not acquired for the purpose of influencing or changing control of the issuer. No single managed portfolio under the parent company owns more than 5% of the outstanding common stock.